This segment focuses on the research, development, manufacturing, and commercialization of rapid diagnostic tests for infectious diseases. Wondfo Biotech utilizes lateral flow immunoassay technology and other point-of-care testing (POCT) methodologies to develop tests for diseases such as COVID-19, influenza, and sexually transmitted infections (STIs). The company's R&D efforts are focused on improving test accuracy, sensitivity, and ease of use, with the goal of providing rapid and reliable results in various settings, including clinics, hospitals, and point-of-care locations. These tests enable early detection and timely treatment, leading to improved patient outcomes and reduced disease transmission. Wondfo's market positioning is strong in China and expanding globally, with a competitive advantage in its established distribution network and strong brand recognition. Future opportunities include expanding the test menu to cover emerging infectious diseases and developing more sophisticated diagnostic platforms.

This segment concentrates on developing and providing diagnostic solutions for the management of chronic diseases, including diabetes, cardiovascular diseases, and certain types of cancers. Wondfo Biotech offers a range of products, including immunofluorescence devices and dry chemistry analyzers, to detect biomarkers related to these conditions. The company's R&D activities involve developing new assays and improving existing ones to enhance the accuracy and efficiency of chronic disease monitoring. The technologies used include immunofluorescence, which allows for the detection of low concentrations of biomarkers, and dry chemistry, which simplifies testing procedures. These solutions enable healthcare professionals to monitor disease progression, assess treatment effectiveness, and improve patient outcomes. Wondfo Biotech aims to strengthen its market position by expanding its product portfolio and entering new markets. Future growth will be driven by the increasing prevalence of chronic diseases and the growing demand for accessible and reliable diagnostic tools.

This segment focuses on the development, manufacturing, and distribution of rapid tests for the detection of drugs of abuse. Wondfo Biotech's drug of abuse tests utilize lateral flow immunoassay technology to provide quick and reliable results for various substances, including opioids, amphetamines, and cannabinoids. The company's R&D efforts are focused on improving the sensitivity and specificity of these tests, as well as expanding the range of detectable substances. These tests are used in a variety of settings, including workplaces, rehabilitation centers, and law enforcement agencies, to promote safety and prevent drug-related harm. Wondfo Biotech aims to maintain its market position by offering a comprehensive portfolio of drug of abuse tests and providing excellent customer service. Future opportunities include developing tests for new and emerging drugs of abuse and expanding into new geographic markets.